CD44 and cancer: Likewise, 92% of the Hs-578t cancer cells showed the CD44+/CD24− immunophenotype, whereas the CD24−/CD44−, CD24+/CD44+, and CD44−/CD24+ subpopulations constituted 7.7%, 0.2%, and 0%, respectively (Figure 1D–F).